Why the study?
Heart failure remains a leading cause of morbidity and mortality globally, requiring updated, patient-centric recommendations based on contemporary evidence to prevent, diagnose, and manage patients.
This executive summary outlines the updated 2022 AHA/ACC/HFSA clinical practice guidelines for the prevention, diagnosis, and management of heart failure.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“One primary goal with the new guideline was to use recently published data to update our recommendations for the evaluation and management of heart failure. One focus was prevention of heart failure through optimizing blood pressure control and adherence to a healthy lifestyle.”
“In recent years, there has been an increase in rigorous science assessing how best to treat symptomatic heart failure.”
“We have four medications to save lives and improve outcomes more than ever, and that therapy is standard core therapy with four drug classes... that can be initiated and optimized as soon as possible: that should be clear. Every patient with reduced EF should have optimization of these four classes.”
Updates HF prevention, diagnosis, and management recommendations; extends 2013/2017 guidelines with evidence through 2020.
AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. METHODS: A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. Structure: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a review in Heart failure. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure was evaluated. The 2022 AHA/ACC/HFSA Guideline provides updated, evidence-based recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: